AstraZeneca's Evusheld Drug Approved by EU for Covid-19 Treatment
20 September 2022 - 8:42AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Tuesday that its Evusheld long-acting
antibody combination has been approved in the European Union for
the treatment of patients with Covid-19.
The Anglo-Swedish pharmaceutical giant said that the European
Commission's approval is based on the Tackle Phase 3 treatment
data, which proved that Evusheld statistically significantly
reduced the risk of severe Covid-19 or death, and that the drug was
well tolerated.
The company's drug would be used for patients aged 12 years old
and older who don't require supplemental oxygen but who are at
increased risk of severe Covid-19, it added.
Evusheld was granted marketing authorization in the EU for the
prevention of coronavirus in March, and is already available in the
majority of countries in Europe.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
September 20, 2022 02:27 ET (06:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
